This article was originally published in The Gray Sheet
Executive SummaryMagnetic resonance imaging device developer nets approximately $4.7 mil. from recently completed oversubscribed initial public offering. Underwritten by D.H. Blair, the offering involved the sale of 1 mil. units at $6 per share; each unit consisted of one share of Class A common stock, one redeemable Class A warrant and one redeemable Class B warrant. The Hicksville, New York-based firm filed a registration statement last December proposing an offering of 833,000 units ("The Gray Sheet" Jan. 18, I&W-3).
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.